SAMHSA, S.A.A.M.H.S.A., Key substance use and mental health indicators in the United States: results from the 2021 National Survey on Drug Use and Health, in Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. 2021, HHS.

WHO, W.H.O. Depressive disorder (depression). 2023; https://www.who.int/news-room/fact-sheets/detail/depression.

Goodwin GM, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637–48.

Article  CAS  PubMed  Google Scholar 

Griffiths RR, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ross S, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30:1165–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sloshower J, et al. Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial. J Psychopharmacol. 2023;37:698–706.

Article  CAS  PubMed  Google Scholar 

Holze F, et al. Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study. Biol Psychiatry. 2023;93:215–23.

Article  CAS  PubMed  Google Scholar 

Raison CL, et al. Effects of naturalistic psychedelic use on depression, anxiety, and well-being: associations with patterns of use, reported harms, and transformative mental states. Front Psychiatry. 2022;13:831092.

Article  PubMed  PubMed Central  Google Scholar 

Lea T, et al. Microdosing psychedelics: motivations, subjective effects and harm reduction. Int J Drug Policy. 2020;75:102600.

Article  PubMed  Google Scholar 

Fadiman, J., The psychedelic explorer’s guide: safe, therapeutic, and sacred journeys. Park Street Press; 2011. p. 352.

Hutten N, Mason NL, Dolder PC, Kuypers KPC. Self-rated effectiveness of microdosing with psychedelics for mental and physical health problems among microdosers. Front Psychiatry. 2019;10:672.

Article  PubMed  PubMed Central  Google Scholar 

de Wit H, et al. Repeated low doses of LSD in healthy adults: a placebo-controlled, dose-response study. Addict Biol. 2022;27:e13143.

Article  PubMed  PubMed Central  Google Scholar 

Bershad AK, et al. Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol Psychiatry. 2019;86:792–800.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Murray CH, et al. Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults. Psychopharmacology. 2022;239:1735–47.

Article  CAS  PubMed  Google Scholar 

Murphy RJ, et al. Acute mood-elevating properties of microdosed lysergic acid diethylamide in healthy volunteers: a home-administered randomized controlled trial. Biol Psychiatry. 2023;94:511–21.

Article  CAS  PubMed  Google Scholar 

Polito V, Liknaitzky, P. The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field. Neurosci Biobehav Rev. 2022;139:104706.

Article  PubMed  Google Scholar 

Cavanna F, et al. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. Transl Psychiatry. 2022;12:307.

Article  PubMed  PubMed Central  Google Scholar 

Marschall J, et al. Psilocybin microdosing does not affect emotion-related symptoms and processing: a preregistered field and lab-based study. J Psychopharmacol. 2022;36:97–113.

Article  PubMed  Google Scholar 

Glazer J, et al. Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity. Neuropsychopharmacology. 2023;48:418–26.

Article  PubMed  Google Scholar 

Szigeti B, et al. Self-blinding citizen science to explore psychedelic microdosing. eLife. 2021;10:e62878.

Kaertner LS, et al. Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. Sci Rep. 2021;11:1941.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holze F, et al. Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants. Clin Pharm Ther. 2021;109:658–66.

Article  CAS  Google Scholar 

Holze F, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2021;46:537–44.

Article  CAS  PubMed  Google Scholar 

Passie T, et al. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008;14:295–314.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beck AT, Steer RA, & Brown G. Beck Depression Inventory–II (BDI-II), in APA PsycTests. 1996.

Association I.S.M. Beck Depression Inventory Scoring. Available from: https://www.ismanet.org/doctoryourspirit/pdfs/Beck-Depression-Inventory-BDI.pdf.

OHSU. Beck Depression Inventory. Available from: https://www.ohsu.edu/sites/default/files/2019-06/Beck%20Depression%20Inventory.pdf.

MAPS. Beck Depression Inventory II. Scoring guide]. Available from: https://maps.org/images/pdf/Beck-Depression-Inventory-Real-Time-Report.pdf.

University of Wisconsin-Madison. Beck Depression Inventory (BDI). Available from: https://arc.psych.wisc.edu/self-report/beck-depression-inventory-bdi/.

Fischman MW, Foltin RW. Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict. 1991;86:1563–70.

Article  CAS  PubMed  Google Scholar 

Morean ME, et al. The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology. 2013;227:177–92.

Article  CAS  PubMed  Google Scholar 

Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharm Ther. 1971;12:245–58.

Article  CAS  Google Scholar 

McNair D, Lorr M, POMS Manual for the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service. 1971.

de Wit H, Griffiths RR. Testing the abuse liability of anxiolytic and hypnotic drugs in humans. Drug Alcohol Depend. 1991;28:83–111.

Article  PubMed  Google Scholar 

Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 1998;31:80–4.

Article  PubMed  Google Scholar 

Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One. 2010;5:e12412.

Article  PubMed  PubMed Central  Google Scholar 

Schmid Y, et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. 2015;78:544–53.

Article  CAS  PubMed  Google Scholar 

Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338:68–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ly C, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moliner R, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26:1032–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Long EE, Haraden DA, Young JF, Hankin BL. Longitudinal patterning of depression repeatedly assessed across time among youth: different trajectories in self-report questionnaires and diagnostic interviews. Psychol Assess. 2020;32:872–82.

Article  PubMed  PubMed Central  Google Scholar 

Balaet M. Psychedelic cognition-the unreached frontier of psychedelic science. Front Neurosci. 2022;16:832375.

Article  PubMed  PubMed Central  Google Scholar